The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs – PLI scheme for pharmaceutical industries
Quantum of Incentive:
Financial incentive under the scheme shall be provided on sales of 41 identified products for six (06) years at the rates given below:
- For fermentation based products, incentive for FY 2023-24 to FY 2026-27 would be 20%, incentive for 2027-28 would be 15% and incentive for 2028-29 would be 5%
- For chemical synthesis based products, incentive for FY 2022-23 to FY 2027-28 would be 10%.
Eligibility
Support under the scheme shall be provided only to manufacturers of critical KSMs/DIs and APIs registered in India.
- Eligibility shall be subject to threshold investment in green field projects
- Eligibility under the scheme shall not affect eligibility under any other scheme and viceversa.
Target Segments
Fermentation based KSMs/Drug Intermediates
1. Penicillin G
2. 7-ACA
3. Erythromycin Thiocynate (TIOC)
4. Clavulanic Acid
II. Fermentation based niche KSMs/Drug Intermediates/APIs
5. Neomycin
6. Gentamycin
7. Betamethasone
8. Dexamethasone
9. Prednisolone
10. Rifampicin
11. Vitamin B1
12. Clindamycin Base
13. Streptomycin
14. Tetracycline III. Key Chemical Synthesis based KSMs/Drug Intermediates
15. 1,1 Cyclohexane Diacetic Acid (CDA)
16. 2-Methyl-5Nitro-Imidazole (2-MNI)
17. Dicyandiamide (DCDA)
18. Para amino phenol IV. Other Chemical Synthesis based KSMs/Drug Intermediates/APIs
19. Meropenem
20. Atorvastatin
21. Olmesartan
22. Valsartan
23. Losartan
24. Levofloxacin
25. Sulfadiazine
26. Ciprofloxacn
27. Ofloxacin
28. Norfloxacin
29. Artesunate
30. Telmisartan
31. Aspirin
32. Diclofenac Sodium
33. Levetiracetam
34. Carbidopa
35. Ritonavir
36. Lopinavir
37. Acyclovir
38. Carbamazepine
39. Oxcarbazepine
40. Vitamin B6
41. Levodop
Eligibility Threshold Criteria
S. No. | . Segment | Threshold Investment |
1 | Fermentation based 04 KSMs /Drug Intermediates | Rs. 400 crore |
2 | Fermentation based 10 niche KSMs / Drug Intermediates / APIs | Rs. 50 crore |
3 | Key Chemical Synthesis based 04 KSMs /Drug Intermediates | Rs. 50 crore |
4 | Other 23 Chemical Synthesis based KSMs / Drug Intermediates / APIs | Rs. 20 crore |
Add a Comment